Tanabe Pharma Corporation
CompanyJapanROR
Tanabe Pharma Corporation develops 3 assets, the furthest approved (canagliflozin in albuminuria). Mostly small molecule acting on Insulin/IGF-1 signalling, lipid and ceramide metabolism and glycolysis; based in Japan.
- Assets
- 3
- Furthest
- Approved
- Trials
- 17
- Signals
- 1
Pipeline
3Sodium-glucose cotransporter 2 (SGLT2) inhibitor that lowers blood glucose by increasing urinary glucose excretion.
ApprovedSmall moleculeAMPK signallingInsulin/IGF-1 signallingalbuminuriacardiovascular death
Bile acid that decreases intestinal cholesterol absorption and protects hepatocytes
ApprovedSmall moleculeApoptosisLipid and ceramide metabolismprimary biliary cholangitissystemic disease
DPP-4 inhibitor improving glycemic control
Phase 3Small moleculeInsulin/IGF-1 signallingGlycolysistype 2 diabetes
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms10
- Trials17
- Signals1
- Similar companies6
Updated 7 Oct 2026 · 64 sources